North America Cervical Cancer Diagnostics and Therapeutics Market by diagnostics test , by therapies (surgery, radiation therapy, chemotherapy and others), by end-users (hospitals, laboratories, independent physicians, clinics, and others), and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)
The North America Cervical Cancer Diagnostics and Therapeutics market has been estimated at USD 1168.20 Million in 2016 and is projected to reach USD 1414.47 Million by 2021, at a CAGR of 3.90% during the forecast period from 2016 to 2021. Cervical cancer was once one of the most common causes of cancer death for American women. But over the last 40 years, the cervical cancer death rate has gone down by more than 50%.
The main reason for this change was the increased use of the Pap test. This screening procedure can find changes in the cervix before cancer develops.
It can also find cervical cancer early − in its most curable stage.
The North American market for Cervical Cancer Diagnostics and Therapeutics is mainly driven due to increasing prevalence of human papillomavirus infected patients and increasing awareness in people about cancer and cancer treatments. However, high costs of tests and uncertain reimbursement rates are constraining the market growth in this region.
View Full Report @ www.marketdataforecast.com/market-…utics-market-830/
North America market for Cervical Cancer Diagnostics and Therapeutics is segmented based on diagnostics test, methods, end-users and therapies. By Diagnostics test, the market is further sub-segmented into Pap smear test, HPV testing, colposcopy, cervical cancer biopsy.
By methods, the market is further sub-segmented into molecular method, cytopathological method, physical method. By therapies, the market is further sub-segmented into surgery, radiation therapy, chemotherapy and others.
By end-users, the market is further sub-segmented into hospitals, laboratories, independent physicians, clinics, and others. Pap smear test segment dominated the market by Diagnostic test, holding a 45% share in the global market for cervical cancer diagnostic tests.
The high growth rate of this segment can be attributed to the high efficiency of the test, low cost of the test in comparison with other tests available in the market, and rising awareness regarding cancer diagnosis.
Free sample of the report is available @ www.marketdataforecast.com/market-…30/request-sample
Geographically, North America market for Cervical Cancer Diagnostics and Therapeutics is segmented into U.S. and Canada. A number of factors such as rising prevalence of cervical cancer, growing awareness of cervical cancer screening programs, and government support are driving the growth of the HPV testing market in the North American region.
Abbott Diagnostics, Alere, Beckman Coulter, Clinical Genomics, Companion Dx, EDP Biotech, Epigenomics AG, Exact Sciences, Fujirebio, Genomic Tree, Metabiomics, Oncocyte (Biotime), Quest Diagnostics, Randox Laboratories, Siemens Healthcare, Volition Rx, are the major players of North America Cervical Cancer Diagnostics and Therapeutics market.
Inquire report @ www.marketdataforecast.com/market-…arket-830/inquire
Category: Market Research Publishers and RetailersCompany about: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...
For more information:Make an Inquiry about this report HERE!